Based on the Xeris Pharmaceuticals Inc stock forecast from 3 analysts, the average analyst target price for Xeris Pharmaceuticals Inc is USD 5.32 over the next 12 months. Xeris Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Xeris Pharmaceuticals Inc is Slightly Bullish , which is based on 4 positive signals and 3 negative signals. At the last closing, Xeris Pharmaceuticals Inc’s stock price was USD 4.16. Xeris Pharmaceuticals Inc’s stock price has changed by -5.67% over the past week, -5.24% over the past month and +117.80% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for Xeris Pharmaceuticals Inc
No recent average analyst rating found for Xeris Pharmaceuticals Inc
Company Overview Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Read Less
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy ...Read More
Frequently Asked Questions About Xeris Pharmaceuticals Inc (XERS) Stock
Based on ratings from 3 analysts Xeris Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 3 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on XERS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for XERS is USD 5.32 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on XERS's stock to indicate if its overvalued.
The last closing price of XERS's stock was USD 4.16.
The most recent market capitalization for XERS is USD 0.65B.
Based on targets from 3 analysts, the average taret price for XERS is projected at USD 5.32 over the next 12 months.
This means that XERS's stock price may go up by +27.88% over the next 12 months.
We can't find any ETFs which contains Xeris Pharmaceuticals Inc's stock.
As per our most recent records Xeris Pharmaceuticals Inc has 0 Employees.
Xeris Pharmaceuticals Inc's registered address is 180 North LaSalle Street, Chicago, IL, United States, 60601.
You can get more information about it from Xeris Pharmaceuticals Inc's website at https://www.xerispharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Xeris Pharmaceuticals Inc (XERS) Stock
Based on ratings from 3 analysts Xeris Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 3 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on XERS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for XERS is USD 5.32 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on XERS's stock to indicate if its overvalued.
The last closing price of XERS's stock was USD 4.16.
The most recent market capitalization for XERS is USD 0.65B.
Based on targets from 3 analysts, the average taret price for XERS is projected at USD 5.32 over the next 12 months.
This means that XERS's stock price may go up by +27.88% over the next 12 months.
We can't find any ETFs which contains Xeris Pharmaceuticals Inc's stock.
As per our most recent records Xeris Pharmaceuticals Inc has 0 Employees.
Xeris Pharmaceuticals Inc's registered address is 180 North LaSalle Street, Chicago, IL, United States, 60601.
You can get more information about it from Xeris Pharmaceuticals Inc's website at https://www.xerispharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for XERS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
